Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019

Abstract

Objective Our objective was to evaluate the safety and efficacy of casirivimab/imdevimab therapy in pregnant women with severe coronavirus disease 2019 (COVID-19) requiring oxygen therapy.

Study Design This was a prospective case series study aimed to evaluate the safety and efficacy of casirivimab/imdevimab therapy in unvaccinated pregnant women with severe COVID-19. Inclusion criteria were severe acute respiratory syndrome coronavirus 2 infection documented with polymerase chain reaction, pregnancy, severe COVID-19 requiring oxygen therapy, duration of symptoms of 10 days or less, and able to provide informed consent. Vaccinated women and those with mild-to-moderate disease were excluded from the study. Included patients received casirivimab and imdevimab as a single intravenous dose of 4,000/4,000 mg. Women were also treated with low molecular weight heparin, steroids, and antibiotics, if necessary. The primary outcome was maternal death. Secondary outcomes were the rate of adverse events during infusion or within 72 hours and the rate of abortion.

Results Thirteen hospitalized unvaccinated pregnant women with severe COVID-19 requiring oxygen and treated with casirivimab/imdevimab were included in the study. We observed no maternal death, and no patients required intubation or admission to the intensive care unit. No abortion or fetal loss was recorded. Nine pregnancies were still ongoing, and there were three cesarean deliveries and one vaginal delivery. Two were preterm deliveries (at 31 and 34 weeks), and two were term deliveries.

Conclusion Casirivimab/imdevimab therapy may be considered as a therapy in unvaccinated pregnant women with severe COVID-19.

Keywords

COVID-19 - infection - intensive care unit - preterm birth

Publication History

Received: 05 March 2022

Accepted: 11 August 2022

Accepted Manuscript online:
16 August 2022

Article published online:
29 December 2022

• References

• 1 WAPM. (The World Association of Perinatal Medicine) working group on COVID-19. Maternal and perinatal outcomes of pregnant women with SARS-COV-2 infection. Ultrasound Obstet Gynecol 2021; 57 (02) 232-241
• 2 Saccone G, Carbone FI, Zullo F. The novel coronavirus (2019-nCoV) in pregnancy: what we need to know. Eur J Obstet Gynecol Reprod Biol 2020; 249: 92-93
• 3 Di Mascio D, Khalil A, Saccone G. et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020; 2 (02) 100107
• 4 Boelig RC, Manuck T, Oliver EA. et al. Labor and delivery guidance for COVID-19. Am J Obstet Gynecol MFM 2020; 2 (02) 100110
• 5 Boelig RC, Saccone G, Bellussi F, Berghella V. MFM guidance for COVID-19. Am J Obstet Gynecol MFM 2020; 2 (02) 100106
• 6 Boelig RC, Aagaard KM, Debbink MP, Shamshirsaz AA. Research Committee, Society for Maternal-Fetal Medicine (SMFM), SMFM Research Committee. Electronic address: [e-mail]. Society for maternal-fetal medicine special statement: COVID-19 research in pregnancy: progress and potential. Am J Obstet Gynecol 2021; 225 (06) B19-B31
• 7 Benski C, Di Filippo D, Taraschi G, Reich MR. Guidelines for pregnancy management during the COVID-19 pandemic: a public health conundrum. Int J Environ Res Public Health 2020; 17 (21) 8277
• 8 United States Food and Drug Administration. Fact sheet for health care providers. Emergency use authorization (EUA) of REGEN-COVTM (casirivimab and imdevimab). Accessed December 10, 2021 at: https://www.fda.gov/media/145611/download
• 9 Gentile I, Maraolo AE, Buonomo AR. et al. Monoclonal antibodies against SARS-CoV-2: potential game-changer still underused. Int J Environ Res Public Health 2021; 18 (21) 11159
• 10 Mayer C, VanHise K, Caskey R, Naqvi M, Burwick RM. Monoclonal antibodies casirivimab and imdevimab in pregnancy for coronavirus disease 2019 (COVID-19). Obstet Gynecol 2021; 138 (06) 937-939
• 11 RECOVERY Colalborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399 (10325): 665-676
• 12 Somersan-Karakaya S. et al. REGEN-COV® for treatment of hospitalized patients with Covid-19. medRxiv
• 13 Adhikari EH, SoRelle JA, McIntire DD, Spong CY. Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge. Am J Obstet Gynecol 2022; 226 (01) 149-151
• 14 Wang AM, Berry M, Moutos CP. et al. Association of the delta (B.1.617.2) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with pregnancy outcomes. Obstet Gynecol 2021; 138 (06) 838-841
• 15 Saad AF, Chappell L, Saade GR, Pacheco LD. Corticosteroids in the management of pregnant patients with coronavirus disease (COVID-19). Obstet Gynecol 2020; 136 (04) 823-826
• 16 Catlin NR, Bowman CJ, Campion SN. et al. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M^pro inhibitor in animal models. Reprod Toxicol 2022; 108: 56-61
• 17 Royal College of Obstetricians and Gynecologist - Coronavirus (COVID-19), infection in pregnancy - updated Monday 07 March 2022. Accessed September 1, 2022 at: https://www.rcog.org.uk/guidance/coronavirus-covid-19-pregnancy-and-women-s